681508-70-3

Basic information

• Product Name: 1-(4-Trifluoromethylphenyl)piperidin-4-ol
• Synonyms: 1-(4-TRIFLUOROMETHYLPHENYL)PIPERIDIN-4-OL;4-(6-Bromo-pyridin-2-yl)-benzoicacid
• CAS NO: 681508-70-3
• Molecular Formula: C₁₂H₁₄F₃NO
• Molecular Weight: 245.24
• Mol File: 681508-70-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 334.3°C at 760 mmHg
• Flash Point: 156°C
• Appearance: /
• Density: 1.275g/cm³
• Vapor Pressure: 5.09E-05mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: 2-8°C
• PKA: 14.72±0.20(Predicted)
• CAS DataBase Reference: 1-(4-Trifluoromethylphenyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Trifluoromethylphenyl)piperidin-4-ol(681508-70-3)
• EPA Substance Registry System: 1-(4-Trifluoromethylphenyl)piperidin-4-ol(681508-70-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 681508-70-3(Hazardous Substances Data)

Usage

General Description

1-(4-Trifluoromethylphenyl)piperidin-4-ol is a complex organic compound that includes a phenyl group (a functional group composed of a ring of carbon atoms, known as a benzene ring), a piperidine ring (a six-membered ring with one nitrogen atom), and a trifluoromethyl group (a component containing a carbon atom bonded to three fluorine atoms). This molecule contains the functional group -OH, making it an alcohol. It can be used in the synthesis of various other chemicals, potentially serving as an intermediate in the production of pharmaceuticals or other high-value compounds. Information regarding its safety, environmental impact or toxicity may vary and should be reviewed thoroughly in the context of its proposed use.

InChI:InChI=1/C12H14F3NO/c13-12(14,15)9-1-3-10(4-2-9)16-7-5-11(17)6-8-16/h1-4,11,17H,5-8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 402-44-8 4-Fluorobenzotrifluoride 

Downstream Products

• 948022-59-1 C₂₀H₁₇F₃N₂O₂ 
• 120807-29-6 1-[4-(trifluoromethyl)phenyl]-4-piperidinone 
• 1160786-75-3 N-(1-benzylpiperidin-4-yl)-6-(1-(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)-2-naphthamide 
• 1160786-77-5 tert-butyl 4-(6-(1-(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)quinoline-3-carboxamido)piperidine-1-carboxylate 
• 1160786-82-2 N-(1-benzylpiperidin-4-yl)-5-(1-(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)-1H-indole-2-carboxamide 
• 1152424-94-6 5-(1-(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)-2,3-dihydro-1H-inden-1-one 
• 1152423-70-5 tert-butyl 4-(6-(1-(4-(trifluoromethyl)phenyl)piperidin4-yloxy)pyridine-3-sulfonamido)piperidine-1-carboxylate 
• 1152423-58-9 N-(1-(pyridin-4-ylmethyl)piperidin-4-yl)-6-(1-(4-(trifluoromethyl)phenyl)piperidin4-yloxy)picolinamide 
• 1247029-07-7 [1-(4-trifluoromethyl-phenyl)-piperidin-4-yloxy]-acetic acid tert-butyl ester 

Relevant articles and documents

NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA

The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds

Solar-driven tandem photoredox nickel-catalysed cross-coupling using modified carbon nitride

Nickel-catalysed aryl amination and etherification are driven with sunlight using a surface-modified carbon nitride to extend the absorption of the photocatalyst into a wide range of the visible region. In contrast to traditional homogeneous photochemical methodologies, the lower cost and higher recyclability of the metal-free photocatalyst, along with the use of readily available sunlight, provides an efficient and sustainable approach to promote nickel-catalysed cross-couplings. This journal is

INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.